Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Review Memo, March 18, 2011 - Hemacord

March 18, 2011 

Our STN: BL 125397/0
New York Blood Center
Attention: Edwin W. Streun
Director, NYBC Regulatory Affairs
310 East 67th Street
New York, NY 10021
Dear Mr. Streun:
We have reviewed your submission dated January 7, 2011 to your biologics license application (BLA) for Hematopoietic Progenitor Cells, Cord (HPC-C) requesting a proprietary name review.
In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, HEMACORD is acceptable at this time.
We will perform another proprietary name review of HEMACORD closer to the time of the action due date to ensure that we have not approved a conflicting proprietary name for another product in the interim.
If you have any questions, please contact the Regulatory Project Manager, Terrolyn Thomas, M.S., M.B.A at (301) 827-6536
Sincerely yours,
Raj K. Puri, M.D., Ph.D.
Division of Cellular and Gene Therapies
Office of Cellular, Tissue, and Gene Therapies
Center for Biologics Evaluation and Research

Page Last Updated: 09/24/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English